SYNTAX Score II 2020: A Remake Worth the Price of Admission?
John J. Squiers, M.D.
Squiers, J. J. and J. M. DiMaio (2021). “SYNTAX Score II 2020: A Remake Worth the Price of Admission?” J Am Coll Cardiol 78(12): 1239-1241.
The SYNTAX score has been widely applied in clinical trial design and clinical practice to objectively measure and stratify the anatomical complexity of coronary artery disease (CAD) (1). Calculation of the SYNTAX score to inform heart team decision-making for patients with multivessel CAD has also been recommended in the 2014 American guidelines and 2018 European guidelines. Defining the complexity of CAD by the SYNTAX score has proven useful as an independent predictor of long-term survival and major adverse cardiovascular events (MACE) in patients undergoing percutaneous coronary intervention (PCI) but not those undergoing coronary artery bypass grafting (CABG). Thus, the value of the SYNTAX score for treatment selection between CABG and PCI by the heart team is uncertain. [No abstract; excerpt from article].